<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208480</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000685975</org_study_id>
    <secondary_id>KCSG-0905</secondary_id>
    <nct_id>NCT01208480</nct_id>
  </id_info>
  <brief_title>Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer</brief_title>
  <official_title>A Phase II Trial of Neoadjuvant Bevacizumab, Docetaxel and Carboplatin for Triple Negative Breast Cancer (Neat Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as&#xD;
      docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either&#xD;
      by killing the cells or by stopping them from dividing. Giving bevacizumab together with&#xD;
      docetaxel and carboplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bevacizumab together with docetaxel&#xD;
      and carboplatin works in treating women with operable Stage II or stage III breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the rate of pathological complete response in women with operable&#xD;
           triple-negative breast cancer treated with neoadjuvant bevacizumab, docetaxel, and&#xD;
           carboplatin.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive bevacizumab IV, docetaxel IV, and carboplatin IV on day 1. Treatment repeat&#xD;
      every 3 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients receive docetaxel IV and carboplatin IV only during course 6. Patients undergo&#xD;
      surgery between weeks 19-21 as planned.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response (pCR)after completion of 6th cycle neoadjuvant treatment</measure>
    <time_frame>After completion of 6 cycle of neoadjuvant chemotherapy followed by surgery</time_frame>
    <description>Primary end point in our study is pCR after 6 cycle of neoadjuvant treatment followed by surgery</description>
  </primary_outcome>
  <enrollment type="Actual">45</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin, docetaxel, carboplatin</intervention_name>
    <description>Avastin, docetaxel, carboplatin</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer&#xD;
&#xD;
               -  Stage II or III disease&#xD;
&#xD;
               -  No evidence of metastasis (M0)&#xD;
&#xD;
               -  No inflammatory breast cancer (T4d)&#xD;
&#xD;
          -  Must have a primary tumor&#xD;
&#xD;
          -  Operable disease&#xD;
&#xD;
          -  Triple-negative disease, meeting the following criteria:&#xD;
&#xD;
               -  Estrogen receptor-, progesterone receptor-, and HER2-negative by&#xD;
                  immunohistochemistry (IHC) 0 or 1+ OR fluorescence in situ hybridization negative&#xD;
                  (in case IHC is 2+)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Pre- or post-menopausal&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥10 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT ≤ 2 times normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times normal&#xD;
&#xD;
          -  Normal or nonspecific EKG&#xD;
&#xD;
          -  LVEF ≥ 50% by MUGA or echocardiogram&#xD;
&#xD;
          -  Normal mental function to understand and sign the written informed consent&#xD;
&#xD;
          -  No history of uncompensated congestive heart failure&#xD;
&#xD;
          -  No history of cancer except for carcinoma in situ of the uterine cervix or nonmelanoma&#xD;
             skin cancer&#xD;
&#xD;
          -  No history or evidence of inherited bleeding diathesis or coagulopathy with the risk&#xD;
             of bleeding&#xD;
&#xD;
          -  No uncontrolled hypertension (systolic BP &gt; 150 mm Hg and/or diastolic BP &gt; 100 mm Hg)&#xD;
&#xD;
          -  No history or evidence of clinically significant cardiovascular disease, including any&#xD;
             of the following:&#xD;
&#xD;
               -  Cerebrovascular accident (CVA) or stroke within the past 6 months&#xD;
&#xD;
               -  Myocardial infarction (MI) within the past 6 months&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  NYHA class II-IV congestive heart failure&#xD;
&#xD;
               -  Serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  No serious nonhealing wound, peptic ulcer, or bone fracture&#xD;
&#xD;
          -  No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal&#xD;
             abscess within the past 6 months&#xD;
&#xD;
          -  No known hypersensitivity to any of the study drugs&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior hormone therapy, chemotherapy, or radiotherapy for breast cancer&#xD;
&#xD;
          -  No prior breast surgery other than biopsy to confirm diagnosis&#xD;
&#xD;
          -  No concurrent chronic daily corticosteroids (more than 10 mg/day methylprednisolone&#xD;
             equivalent)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo Hyuk Sohn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>April 9, 2012</last_update_submitted>
  <last_update_submitted_qc>April 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Severance Hospital</investigator_affiliation>
    <investigator_full_name>Joohyuk Sohn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>triple-negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

